Sihuan Pharmaceutical Holdings Group (DB:TEL1) - Stock Price, News & Analysis

TEL1 Stock Overview

TEL1 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Cotiza un 40.5% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 119.42%

Trading a buen valor en comparación con empresas similares e industria

Risk Analysis

No risks detected for TEL1 from our risk checks.

Sihuan Pharmaceutical Holdings Group Ltd. Competitors

PharmaSGP Holding

XTRA:PSG

€266.4m

Dermapharm Holding

XTRA:DMP

€1.7b

MPH Health Care

DB:93M1

€89.9m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of all time highs, changes and price drops for Sihuan Pharmaceutical Holdings Group
Historical stock prices
Current Share Price	HK$0.058
52 Week High	HK$0.10
52 Week Low	HK$0.056
Beta	0.68
1 Month Change	-2.54%
3 Month Change	-14.81%
1 Year Change	-43.63%
3 Year Change	-73.38%
5 Year Change	-73.00%
Change since IPO	-79.17%

Recent updates

Shareholder Returns

	TEL1	DE Pharmaceuticals	DE Market
7D	-1.7%	-6.0%	-1.3%
1Y	-43.6%	-31.5%	4.1%

Rentabilidad frente al sector: TEL1 obtuvo unos resultados inferiores a los del sector German Pharmaceuticals , que el año pasado arrojó un rendimiento del -30.7%.

Rentabilidad vs. Mercado: TEL1 obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.

Price Volatility

Is TEL1's price volatile compared to industry and market?
TEL1 volatility
TEL1 Average Weekly Movement	6.5%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.7%
10% most volatile stocks in DE Market	9.7%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: TEL1 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de TEL1 (6%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
2001	2,872	Weicheng Guo	https://www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd., sociedad de cartera de inversiones, se dedica a la investigación y desarrollo, fabricación, comercialización y venta de productos farmacéuticos y médico-estéticos en la República Popular China. Ofrece fármacos en las áreas terapéuticas de oncología, metabolismo, diabetes, cardiovascular y cerebrovascular, medicina china moderna y cáñamo industrial. La empresa también se dedica a la inversión y venta de productos médicos de belleza; la fabricación de instrumentos médicos; la inversión en propiedades; la construcción para proyectos médicos; y la preparación de proyectos para la fabricación de productos farmacéuticos.

Sihuan Pharmaceutical Holdings Group Ltd. Fundamentals Summary

How do Sihuan Pharmaceutical Holdings Group's earnings and revenue compare to its market cap?
TEL1 fundamental statistics
Market cap	€568.91m
Earnings (TTM)	-€6.89m
Revenue (TTM)	€237.36m

2.4x

P/S Ratio

-82.6x

P/E Ratio

Is TEL1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TEL1 income statement (TTM)
Revenue	CN¥1.86b
Cost of Revenue	CN¥564.90m
Gross Profit	CN¥1.30b
Other Expenses	CN¥1.35b
Earnings	-CN¥54.02m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0058
Gross Margin	69.64%
Net Profit Margin	-2.90%
Debt/Equity Ratio	22.9%

How did TEL1 perform over the long term?

See historical performance and comparison

TEL1 Stock Overview

Rewards

Risk Analysis

Sihuan Pharmaceutical Holdings Group Ltd. Competitors

XTRA:PSG

€266.4m

XTRA:DMP

€1.7b

DB:93M1

€89.9m

DB:2FJ0

€92.8m

Price History & Performance

Recent News & Updates

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

Now 21% undervalued

Now 21% undervalued after recent price drop

Recent updates

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

Now 21% undervalued

Now 21% undervalued after recent price drop

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.045 profit in FY 2021)

Now 24% undervalued after recent price drop

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Now 21% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: €0.27

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

New 90-day high: €0.25

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: €0.24

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released

Deputy General Manager recently bought €2.1m worth of stock

First half earnings released

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Shareholder Returns

Price Volatility